Iadademstat in Combination with Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (ALICE): An Open-Label, Phase IIa Dose-Finding Study

In a phase III trial, patients with newly diagnosed chronic myeloid leukemia were randomly assigned in a 1:1 ratio to receive either asciminib or an investigator-selected tyrosine kinase inhibitor.